Ikena Oncology Inc (IKNA)
1.42
+0.02
(+1.43%)
USD |
NASDAQ |
May 17, 16:00
1.43
+0.01
(+0.70%)
After-Hours: 20:00
Ikena Oncology Enterprise Value: -88.34M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | -88.34M |
| May 16, 2024 | -89.79M |
| May 15, 2024 | -92.92M |
| May 14, 2024 | -93.17M |
| May 13, 2024 | -93.65M |
| May 10, 2024 | -95.10M |
| May 09, 2024 | -92.20M |
| May 08, 2024 | -91.24M |
| May 07, 2024 | -89.31M |
| May 06, 2024 | -94.13M |
| May 03, 2024 | -93.65M |
| May 02, 2024 | -93.65M |
| May 01, 2024 | -94.61M |
| April 30, 2024 | -93.65M |
| April 29, 2024 | -93.17M |
| April 26, 2024 | -94.61M |
| April 25, 2024 | -94.13M |
| April 24, 2024 | -95.10M |
| April 23, 2024 | -92.20M |
| April 22, 2024 | -94.61M |
| April 19, 2024 | -93.17M |
| April 18, 2024 | -96.54M |
| April 17, 2024 | -97.51M |
| April 16, 2024 | -96.06M |
| April 15, 2024 | -95.58M |
| Date | Value |
|---|---|
| April 12, 2024 | -93.17M |
| April 11, 2024 | -90.75M |
| April 10, 2024 | -96.54M |
| April 09, 2024 | -93.17M |
| April 08, 2024 | -93.65M |
| April 05, 2024 | -92.20M |
| April 04, 2024 | -91.72M |
| April 03, 2024 | -92.92M |
| April 02, 2024 | -92.92M |
| April 01, 2024 | -90.27M |
| March 28, 2024 | -106.94M |
| March 27, 2024 | -108.39M |
| March 26, 2024 | -108.39M |
| March 25, 2024 | -105.97M |
| March 22, 2024 | -104.04M |
| March 21, 2024 | -103.08M |
| March 20, 2024 | -100.42M |
| March 19, 2024 | -103.08M |
| March 18, 2024 | -103.08M |
| March 15, 2024 | -99.70M |
| March 14, 2024 | -105.01M |
| March 13, 2024 | -107.42M |
| March 12, 2024 | -108.39M |
| March 11, 2024 | -105.01M |
| March 08, 2024 | -98.25M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-132.75M
Minimum
Nov 09 2023
944.32M
Maximum
Mar 26 2021
55.58M
Average
1.032M
Median
Apr 05 2022
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 5.156M |
| Palatin Technologies Inc | 22.26M |
| iBio Inc | 16.77M |
| Theriva Biologics Inc | -8.901M |
| Oragenics Inc | 8.862M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.15M |
| Total Expenses (Quarterly) | 15.64M |
| EPS Diluted (Quarterly) | -0.33 |
| Earnings Yield | -109.8% |
| Normalized Earnings Yield | -125.74 |